Financial Disclosure

All affiliations with or financial involvement (e.g., employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, royalties) with any organization or entity with a financial interest in or in financial competition with the subject matter or materials discussed in the manuscript are completely disclosed in the letter of submission.

All financial and material support for this research and work are clearly identified in the manuscript including listing of support specified in the letter of submission that might constitute or give the appearance of influencing the findings, based on the judgment of the Editor-in-Chief in consultation with the Associate Editor handling the review of the manuscript.

All authors will be expected to complete a disclosure statement upon acceptance of any manuscript. Items included in the disclosure statement include: consulting fees or paid advisory boards (for the past two years or the known future), equity ownership/stock options (publicly or privately traded firms, excluding mutual funds), lecture fees when speaking at the invitation of a commercial sponsor (for the past two years or the known future), employment by the commercial entity that sponsored the study, grant support from industry, patents and/or royalties, expert witness, and other activities performed for a commercial sponsor. A link to our online disclosure system will be provided at the time of acceptance.

Link to the Disclosure Form

Financial Disclosure of Executive Board Members

The leadership of JAD will disclose any relevant relationships per the journal’s disclosure policy. These disclosures are updated every 6 months and are available here: http://www.j-alz.com/boarddisclosures